The Posterior First Approach in Robot-assisted Radical Prostatectomy for Prostate Cancer Reduces Positive Surgical Margins on the Bladder Neck Side.
[BACKGROUND/AIM] There is limited data comparing outcomes and quality of life between the conventional robot-assisted radical prostatectomy (RARP) (anterior approach) and the posterior first approach
- 표본수 (n) 255
APA
Nakai Y, Tanaka N, et al. (2025). The Posterior First Approach in Robot-assisted Radical Prostatectomy for Prostate Cancer Reduces Positive Surgical Margins on the Bladder Neck Side.. Anticancer research, 45(11), 5177-5184. https://doi.org/10.21873/anticanres.17857
MLA
Nakai Y, et al.. "The Posterior First Approach in Robot-assisted Radical Prostatectomy for Prostate Cancer Reduces Positive Surgical Margins on the Bladder Neck Side.." Anticancer research, vol. 45, no. 11, 2025, pp. 5177-5184.
PMID
41151904
Abstract
[BACKGROUND/AIM] There is limited data comparing outcomes and quality of life between the conventional robot-assisted radical prostatectomy (RARP) (anterior approach) and the posterior first approach RARP. In the present study, we evaluated the differences between conventional and posterior first approach RARP.
[PATIENTS AND METHODS] This study enrolled consecutive patients who underwent conventional RARP (n=255) and posterior first approach RARP (n=107). Propensity scores were calculated, and patients were matched in a 1:1 ratio based on these scores. The quality of life (QOL), continence, and perioperative outcomes were evaluated in the two groups.
[RESULTS] Using propensity matching, 99 patients were included in each group. The number of patients (75%) whose bladder necks were preserved in the posterior first approach RARP group was significantly higher (<0.001) than that in the conventional RARP group (42%). Positive surgical margin on the side of the bladder neck in the posterior first approach group (1%) was not significantly (=0.03) detected compared to that in the conventional group (8%). There was no significant difference in QOL score at 12 months after RARP or in continence rate within 12 months after RARP.
[CONCLUSION] Compared to the conventional approach, the posterior first approach RARP can preserve the bladder neck and reduce the incidence of positive surgical margins at the bladder neck side.
[PATIENTS AND METHODS] This study enrolled consecutive patients who underwent conventional RARP (n=255) and posterior first approach RARP (n=107). Propensity scores were calculated, and patients were matched in a 1:1 ratio based on these scores. The quality of life (QOL), continence, and perioperative outcomes were evaluated in the two groups.
[RESULTS] Using propensity matching, 99 patients were included in each group. The number of patients (75%) whose bladder necks were preserved in the posterior first approach RARP group was significantly higher (<0.001) than that in the conventional RARP group (42%). Positive surgical margin on the side of the bladder neck in the posterior first approach group (1%) was not significantly (=0.03) detected compared to that in the conventional group (8%). There was no significant difference in QOL score at 12 months after RARP or in continence rate within 12 months after RARP.
[CONCLUSION] Compared to the conventional approach, the posterior first approach RARP can preserve the bladder neck and reduce the incidence of positive surgical margins at the bladder neck side.
MeSH Terms
Humans; Male; Prostatectomy; Prostatic Neoplasms; Robotic Surgical Procedures; Quality of Life; Aged; Margins of Excision; Middle Aged; Urinary Bladder; Treatment Outcome
같은 제1저자의 인용 많은 논문 (3)
- Effect of Celecoxib Combined With Low-Dose-Rate Brachytherapy on Long-Term Oncological Outcomes and Quality of Life in Prostate Cancer: Post Hoc Analysis of an Open-Label Controlled Randomized Trial.
- Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel.
- Evaluating Local Doses for Prostate Cancer Treatment Using Low-Dose-Rate Brachytherapy Considering Oncological Control and Toxicity.